ROIV
Roivant Sciences Ltd

1,948
Mkt Cap
$12.44B
Volume
6.95M
52W High
$18.42
52W Low
$8.73
PE Ratio
-26.07
ROIV Fundamentals
Price
$18.22
Prev Close
$18.12
Open
$18.13
50D MA
$14.60
Beta
0.84
Avg. Volume
9.82M
EPS (Annual)
-$0.2371
P/B
2.86
Rev/Employee
$38,737.33
Loading...
Loading...
News
all
press releases
Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice
Does Roivant Sciences Ltd. (ROIV) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains?
Montes Archimedes Acquisition (ROIV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·1mo ago
News Placeholder
Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17
Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study, the company said.
Stocktwits·1mo ago
News Placeholder
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of +21.74% and -71.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates
Kura Oncology (KURA) delivered earnings and revenue surprises of -600.00% and -89.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -13.64% and +11.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar?
Style Box ETF report for GRPM
Zacks·4mo ago
News Placeholder
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates
Zacks·5mo ago
News Placeholder
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates
Zacks·5mo ago
News Placeholder
Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates
Zacks·6mo ago

Latest ROIV News

View

Advertisement|Remove ads.

Advertisement|Remove ads.